Translate page

-- Virtual Education Program: 2018 Edition


Presentations from the COLT Meeting 2018

We are pleased to make available a series of presentations from the COLT Meeting 2018, a CML Opinion Leader Training that took place in Adelaide (Australia). Topics cover; CML therapy - state of science, practicalities on CML management, TFR in CML, CML related topics and the CML frontier.

Timothy Hughes.pngDavid Yeung 3Devendra Hiwase



Session 1: CML therapy - state of science
Chair: Prof. Tim Hughes

  • CML - current clinical issues
    and future directions 
    (Prof Tim Hughes)
  • When frontline therapy fails
    (Dr David Yeung)
  • CML - Beyond chronic phase
    (Dr Devendra Hiwase)



Timothy Hughes



CML - Current clinical issues and future directions
Prof. Tim Hughes, SAHMRI / University of Adelaide

  • Key issues and possible solutions
  • Essential tests at diagnosis
  • Expected outcome for patients treated with frontline imatinib
  • Risk-adapted/goal specific treatment schema
  • Consensus of opinion on TKI choices
  • Results from the TIDEL II trial in Australia/NZ
  • Results from the TARGET survey
  • ABL001 - specific inhibitor of BCR-ABL1


David Yeung 3  

When frontline therapy fails
Dr David Yeung - SAHMRI / Royal Adelaide Hospital

  • LASOR - failure to achieve 2019 ELN goals
  • TIDEL II - failure to achieve optimal ELN 2013 treatment goals
  • ENESTCmr - failure to achieve deep molecular response
  • Ponatinib - drug of last resort
  • Asciminib (ABL001) - rising star?

Devendra Hiwase


CML - Beyond chronic phase
Dr Devendra Hiwase - SA Pathology / Royal Adelaide Hospital

  • Diagnostic and management issues in CML-AP
    • Definitions of AP
    • Survival benefit with Imatinib in CML-AP
    • Study results on NIL, DAS and PON in patients with CML-AP
    • Imatinib vs. allogeneic SCT in CML-AP patients
    • Treatment strategy recommendations for CML-AP
    • Patient case
  • Diagnostic criteria and management of blast crisis
    • Transformation to blast crisis
    • Survival of CML-BC patients: German CML studies I to IIIA
    • Outcome of blast crisis in the era of TKI therapy
    • Management issues in CML-BC
    • Further treatment options in CML-BC
    • Patient case